Psyence Biomedical Ltd（PBM）股票分析

$0.000

-0.000 (-100.00%)收盤時

Loading chart…

High: 4.370
Open: 4.370
VWAP: 2.85
Vol: 14.69K
Mkt Cap: —
Low: 4.185
Amount: 41.89K
EV/EBITDA, TTM: 0.00

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

psyencebiomed.com/contact

AI analysis of Psyence Biomedical Ltd (PBM)

hold

Psyence Biomedical Ltd is currently priced at $4.57, which is relatively stable but shows a 2.41% increase recently. However, the company reported a significant net loss of $753,254 in Q2 2026, indicating financial challenges. The RSI is at 58.53, suggesting the stock is neither overbought nor oversold, but the forward P/E ratio is at 0, indicating uncertainty in future earnings. While there are positive catalysts such as U.S. government support for ibogaine development, the financial performance raises concerns, making it a hold rather than a buy.

估值指標

The current forward P/E ratio for Psyence Biomedical Ltd (PBM) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued

5Y Average P/E

0.00

Current P/E

0.00

高估

0.00

低估

0.00

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

高估

0.00

低估

0.00

Alphio AI Price Scenarios for PBM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%PBM

$4.72

情境價格

Base

Base · 50%PBM

$4.52

情境價格

Bear

Bear · 25%PBM

$4.35

情境價格

事件時間軸

2026-08-26 (ET)